193 related articles for article (PubMed ID: 22562854)
21. The National Eye Institute, the practicing physician, and the patient.
Kupfer C
Trans Pa Acad Ophthalmol Otolaryngol; 1971; 24(2):110-5. PubMed ID: 5134064
[No Abstract] [Full Text] [Related]
22. Corporate responsibility for recombinant DNA activities.
Berger BA
Univ Toledo Law Rev; 1981; 12(4):913-24. PubMed ID: 11649592
[No Abstract] [Full Text] [Related]
23. Introduction to recombinant DNA research, development and evolution of the NIH guidelines, and proposed legislation.
Talbot B
Univ Toledo Law Rev; 1981; 12(4):804-14. PubMed ID: 11649587
[No Abstract] [Full Text] [Related]
24. The Human Genome Project in the United States: a perspective on the commercial, ethical, legislative and health care issues.
Mackler BF; Barach M
J Int Bioethique; 1991; 2(3):149-57. PubMed ID: 11654898
[TBL] [Abstract][Full Text] [Related]
25. Conflict of interest revisited.
Nature; 1992 Feb; 355(6363):751. PubMed ID: 1538754
[No Abstract] [Full Text] [Related]
26. Should private agencies maintain federal research data?
Boruch RF
IRB; 1984; 6(6):8-9. PubMed ID: 11649194
[No Abstract] [Full Text] [Related]
27. Secrets of the artificial heart business.
Anderson I
New Sci; 1984 Dec; 104(1433):7. PubMed ID: 11655657
[No Abstract] [Full Text] [Related]
28. Working with the CTSA Consortium: what we bring to the table.
Steele SJ
Sci Transl Med; 2010 Dec; 2(63):63mr5. PubMed ID: 21178135
[TBL] [Abstract][Full Text] [Related]
29. Sweeping patent shocks gene therapists.
Coghlan A
New Sci; 1995 Apr; 146(1971):4. PubMed ID: 11656409
[No Abstract] [Full Text] [Related]
30. Definitions and boundaries of research misconduct: perspectives from a federal government viewpoint.
Price AR
J Higher Educ; 1994; 65(3):286-97. PubMed ID: 11653365
[No Abstract] [Full Text] [Related]
31. Regulating biotechnology.
McGarity TO
Issues Sci Technol; 1985; 1(3):40-56. PubMed ID: 11649701
[No Abstract] [Full Text] [Related]
32. Patenting gene fragments.
Agrawal A
Econ Polit Wkly; 1993 May; 28(22):1089-93. PubMed ID: 11660270
[No Abstract] [Full Text] [Related]
33. US science: The Obama experiment.
Tollefson J
Nature; 2012 Sep; 489(7417):488-92. PubMed ID: 23018946
[No Abstract] [Full Text] [Related]
34. Private ethics boards and public debate.
Tauer CA
Hastings Cent Rep; 1999; 29(2):43-5. PubMed ID: 10321344
[No Abstract] [Full Text] [Related]
35. Squabbling all the way to the genebank.
Kleiner K
New Sci; 1994 Nov; 144(1953):14-5. PubMed ID: 11656411
[No Abstract] [Full Text] [Related]
36. Tapping the potential of government-industry collaboration.
Petricciani JC; Gage P
Biologicals; 1996 Sep; 24(3):149-55. PubMed ID: 8978912
[No Abstract] [Full Text] [Related]
37. Gene dream fades away.
Coghlan A
New Sci; 1995 Nov; 148(2005):14-5. PubMed ID: 11656474
[No Abstract] [Full Text] [Related]
38. The price of profit.
Coghlan A
New Sci; 1998 May; 158(2134):20-1. PubMed ID: 11660513
[No Abstract] [Full Text] [Related]
39. Scientific misconduct in academia: a survey and analysis of applicable law.
Sise CB
San Diego Law Rev; 1991; 28(2):401-28. PubMed ID: 11651628
[No Abstract] [Full Text] [Related]
40. FDA issues concerning conflicts of interest.
Kurt TL
IRB; 1990; 12(5):6-9. PubMed ID: 11654003
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
